Clinical efficacy of sildenafil in patients with pulmonary hypertension in functional class II or III;Hipertensión pulmonar: Eficacia clínica del sildenafilo en clases funcionales II-III

Archivos de Bronconeumologia

Volumn 43, Issue 5, 2007, Pages 272-276

  Otero González, Isabel ^a   Aparicio, Marina Blanco ^a   Alonso, Ana Souto ^a   Sonnenfeld, Inés Raposo ^a   Hernando, Héctor Verea ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Clinical efficacy; Inoperable chronic thromboembolic pulmonary hypertension; Pulmonary hypertension; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEADACHE; HUMAN; LUNG ARTERY PRESSURE; MALE; MONOTHERAPY; PULMONARY HYPERTENSION; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREATMENT RESPONSE; WALKING;

EID: 34250357262     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13101954     Document Type: Article

References (27)

1. Rubin LJ. Introduction. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:7S-10S.
2. Doyle RL, McCrory D, Channick RN, Simmoneau G, Conte J. Surgical treatments/interventions for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest. 2004;126:63S-71S.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-36.
4. Caraballo Fonseca JC, Martínez Blanco CD, Sánchez de León R. Disfunción endotelial en la hipertensión pulmonar. Arch Bronconeumol. 2005;41:389-92.
5. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol. Lancet. 1984;1:1046-7.
6. Olschewski H, Simonneau G, Galie N, Higenbottan T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
7. Simonneau G, Barst RJ, Galie N, Naeije R, Rich R, Bourge RC, et al, for the Treprostinil study group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med. 2002;165:800-4.
8. Rubin U, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
9. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al, STRIDE-1 study group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-7.
10. Reffelman T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation. 2003;239:239-44.
11. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya W, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-7.
12. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
13. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1-10.
14. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. ESC guidelines. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004;25:2243-78.
15. Badesch D, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest. 2004;126:S35-S62.
16. Michelackis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-403.
17. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000;343:1342.
18. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Comparison with inhaled nitric oxide. Circulation. 2002;105:2398-403.
19. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J. 2004;25:431-6.
20. Humpl T, Reyes T, Holtby HH, Sthephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Twelve-month clinical trial of a single-drug, open label, pilot study. Circulation. 2005;111:3274-80.
21. Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension. A randomized, placebo-controlled, double blind, crossover study. J Am Coll Cardiol. 2004;43:1149-53.
22. Nagaya N, Sasaki N, Ando M, Ogino H, Sakamaki F, Kyotani S, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. 2003;123:338-43.
23. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003;167:1139-41.
24. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schäfers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2363-7.
25. Galiè N, Alan L, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;42:1380-6.
26. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-92.
27. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long term follow up of primary pulmonary arterial hypertension. Chest. 2005; 128:2368-74.